Theory and practice of size exclusion chromatography for the analysis of protein aggregates

Journal of Pharmaceutical and Biomedical Analysis

Volumn 101, Issue , 2014, Pages 161-173

  Fekete, Szabolcs ^a   Beck, Alain ^b   Veuthey, Jean Luc ^a   Guillarme, Davy ^a  

^a UNIVERSITY OF GENEVA   (Switzerland)

^b Centre d'Immunologie Pierre Fabre   (France)

Author keywords

Aggregates; Biopharmaceuticals; Size exclusion chromatography; Therapeutic proteins

Indexed keywords

PROTEIN; DYES, REAGENTS, INDICATORS, MARKERS AND BUFFERS; PROTEIN AGGREGATE;

DRUG FORMULATION; GEL PERMEATION CHROMATOGRAPHY; LIGHT SCATTERING; MASS SPECTROMETRY; MULTIANGLE LASER LIGHT SCATTERING; PARTICLE SIZE; PROTEIN AGGREGATION; REFRACTION INDEX; REVIEW; SEPARATION TECHNIQUE; ULTRAVIOLET RADIATION; VISCOMETER; CHEMISTRY; GEL CHROMATOGRAPHY; PROCEDURES; REFRACTOMETRY;

CHROMATOGRAPHY, GEL; INDICATORS AND REAGENTS; PARTICLE SIZE; PROTEIN AGGREGATES; PROTEINS; REFRACTOMETRY;

EID: 84908606572     PISSN: 07317085     EISSN: 1873264X     Source Type: Journal    
DOI: 10.1016/j.jpba.2014.04.011     Document Type: Review

References (114)

1. Fekete S., Veuthey J.L., Guillarme D. New trends in reversed-phase liquid chromatographic separations of therapeutic peptides and proteins: theory and applications. J. Pharm. Biomed. Anal. 2012, 69:9-27.
2. Walsh G. Pharmaceuticals, biologics and biopharmaceuticals. Pharmaceutical Biotechnology: Concepts and Applications 2007, 1-11. Wiley, West Sussex, England.
3. www.imshealth.com.(consulted in November 2011).
4. (consulted in November 2011). http://www.portfoliomanagementsolutions.com/the-organization-of-pharmaceutical-rd/small-molecule-drugs-versus-biomolecular-drugs-biologics/.
5. Beck A., Reichert J. Approval of the first biosimilar antibodies in Europe. mAbs 2013, 5:621-623.
6. Krull I.S., Rathore A., Wheat T.E. Current applications of UHPLC in biotechnology. Part I. Peptide mapping and amino acid analysis. LCGC N. Am. 2011, 29:838-848.
7. Diress A., Lorbetskie B., Larocque L., Li X., Alteen M., Isbrucker R., Girard M. Study of aggregation, denaturation and reduction of interferon alpha-2 products by size-exclusion high performance liquid chromatography with fluorescence detection and biological assays. J. Chromatogr. A 2010, 1217:3297-3306.
8. Bucciantini M., Giannoni E., Chiti F., Baroni F., Formigli L., Zurdo J., Taddei N., Ramponi G., Dobson C.M., Stefani M. Inherent toxicity of aggregates implies a common mechanism for protein misfolding diseases. Nature 2002, 416:507-511.
9. Wang W. Protein aggregation and its inhibition in biopharmaceutics. J. Pharm. 2005, 289:1-30.
10. Booth D.R., Sunde M., Bellotti V., Robinson C.V., Hutchinson W.L., Fraser P.E., Hawkins P.N., Dobson C.M., Radford S.E., Blake C.C.F., Pepys M.B. Instability, unfolding and aggregation of human lysozyme variants underlying amyloid fibrillogenesis. Nature 1997, 385:787-793.
11. Beck A., Rousset E.W., Ayoub D., Van Dorsselaer A., Cianferani S.S. Characterization of therapeutic antibodies and related products. Anal. Chem. 2013, 85:715-736.
12. Vazquez-Rey M., Lang D.A. Aggregates in monoclonal antibody manufacturing processes. Biotechnol. Bioeng. 2011, 108(7):1494-1508.
13. Rosenberg A.S. Effects of protein aggregates: an immunologic perspective. AAPS J. 2006, 8(3):E501-E507.
14. Cudd A., Arvinte T., Das R.E.G., Chinni C., Macintyre A. Enhanced potency of human calcitonin when fibrillation is avoided. J. Pharm. Sci. 1995, 84:717-719.
15. Wang W. Instability, stabilization, and formulation of liquid protein pharmaceuticals. J. Pharm. 1999, 185:129-188.
16. Sluzky V., Shahrokh Z., Stratton P., Eberlein G., Wang Y.J. Chromatographic methods for quantitation of native, denaturated and aggregated bFGF in solution formulations. Pharm. Res. 1994, 11:485-490.
17. Uversky V.N. Use of fast protein size-exclusion liquid chromatography to study the unfolding of proteins which denature through the molten globule. Biochemistry 1993, 32:13288-13298.
18. Hartmann W.K., Saptharishi N., Yang X.Y., Mitra G., Soman G. Characterization and analysis of thermal denaturation of antibodies by size exclusion high-performance liquid chromatography with quadruple detection. Anal. Biochem. 2004, 325:227-239.
19. Fraunhofer W., Winter G. The use of asymmetrical flow field-flow fractionation in pharmaceutics and biopharmaceutics. Eur. J. Pharm. Biopharm. 2004, 58:369-383.
20. Ladokhin A.S. Fluorescence spectroscopy in peptide and protein analysis. Encyclopedia of Analytical Chemistry 2000, 5762-5779. John Wiley, New York. R.A. Meyers (Ed.).
21. Kelly S.M., Jess T.J., Price N.C. How to study proteins by circular dichroism. Biochim. Biophys. Acta 2005, 1751:119-139.
22. Beaulieu M., Corredig M., Turgeon S.L., Wicker L., Doublier J.L. The formation of heat-induced protein aggregates in whey protein/pectin mixtures studied by size exclusion chromatography coupled with multi-angle laser light scattering detection. Food Hydrocol. 2005, 19:803-812.
23. Kukrer B., Filipe V., van Duijn E., Kasper P.T., Vreeken R.J., Heck A.J., Jiskoot W. Mass spectrometric analysis of intact human monoclonal antibody aggregates fractionated by size-exclusion chromatography. Pharm. Res. 2010, 27:2197-2204.
24. Beck A., Cianférani S.S., Van Dorsselaer A. Biosimilar, biobetter, and next generation antibody characterization by mass spectrometry. Anal. Chem. 2012, 84:4637-4646.
25. Beck A., Diemer H., Ayoub D., Debaene F., Rousset E.W., Carapito C., Van Dorsselaer A., Cianferani S.S. Analytical characterization of biosimilar antibodies and Fc-fusion proteins. Trends Anal. Chem. 2013, 48:81-95.
26. Fekete S., Ganzler K., Guillarme D. Critical evaluation of fast size exclusion chromatographic separations of protein aggregates, applying sub-2μm particles. J. Pharm. Biomed. Anal. 2013, 78/79:141-149.
27. Diederich P., Hansen S.K., Oelmeier S.A., Stolzenberger B., Hubbuch J. A sub-two minutes method for monoclonal antibody-aggregate quantification using parallel interlaced size exclusion high performance liquid chromatography. J. Chromatogr. A 2011, 1218:9010-9018.
28. Barth H.G., Saunders G.D. The state of the art and future trends of size-exclusion chromatography packing and columns. LCGC N. Am. 2012, 30:544-563.
29. Hong P., Koza S., Bouvier E.S.P. A review, size exclusion chromatography for the analysis of protein biotherapeutics and their aggregates. J. Liq. Chromatogr. Relat. Technol. 2012, 35:2923-2950.
30. Engelhardt H., Ahr G. Optimization of efficiency in size exclusion chromatography. J. Chromatogr. 1983, 282:385-397.
31. Kopaciewicz W., Regnier F.E. Nonideal size-exclusion chromatography of proteins: effects of pH at low ionic strength. Anal. Biochem. 1982, 126:8-16.
32. Arakawa T., Ejima D., Li T., Philo J.S. The critical role of mobile phase composition in size exclusion chromatography of protein pharmaceuticals. J. Pharm. Sci. 2010, 99:1674-1692.
33. Golovchenko N.P., Kataeva I.A., Akimenko V.K. Analysis of pH-dependent protein interactions with gel filtration medium. J. Chromatogr. 1992, 591:121-128.
34. Park S., Cho H., Kim Y., Ahn S., Chang T. Fast size exclusion chromatography at high temperature. J. Chromatogr. A 2007, 1157:96-100.
35. Pasch H., Kilz P. Fast liquid chromatography for high-throughput screening of polymers. Macromol. Rapid Commun. 2003, 24:104-108.
36. Popovici S.T., Schoenmakers P.J. Fast size-exclusion chromatography - theoretical and practical considerations. J. Chromatogr. A 2005, 1099:92-102.
37. Das T., Nema S. Protein particulate issues in biologics development. Am. Pharm. Rev. 2008, 11:54-57.
38. Mahler H., Friess W., Grauschopf U., Kiese S. Protein aggregation: pathways, induction factors and analysis. J. Pharm. Sci. 2009, 98:2909-2934.
39. Wang W. Protein aggregation and its inhibition in biopharmaceutics. Int. J. Pharm. 2005, 289:1-30.
40. Aggregation of Therapeutic Proteins 2010, John Wiley & Sons, Inc., Hoboken, NJ, USA. W. Wang, C.J. Roberts (Eds.).
41. Cleland J.L., Powell M.F., Shire S.J. The development of stable protein formulations: a close look at protein aggregation, deamidation, and oxidation. Crit. Rev. Ther. Drug Carrier Syst. 1993, 10:307-377.
42. Filipe V., Hawe A., Schellekens H., Jiskoot W. Aggregation and immunogenicity of therapeutic proteins. Aggregation of Therapeutic Proteins 2010, 403-433. John Wiley & Sons, Inc., Hoboken, NJ, USA.
43. Brummitt R.K., Nesta D.P., Chang L., Chase S.F., Laue T.M., Roberts C.J. Non-native aggregation of an IgG1 antibody in acidic conditions. 1. Unfolding, colloidal interactions, and formation of high molecular weight aggregates. J. Pharm. Sci. 2011, 100:2087-2103.
44. Brummitt R.K., Nesta D.P., Chang L., Kroetsch A.M., Roberts C.J. Non-native aggregation of an igg1 antibody in acidic conditions. 2. Nucleation-and-growth kinetics with competing growth mechanisms. J. Pharm. Sci. 2011, 100:2104-2119.
45. Sharma V.K., Kalonia D.S. Experimental detection and characterization of protein aggregates. Aggregation of Therapeutic Proteins 2010, 205-256. John Wiley & Sons, Inc., Hoboken, NJ, USA.
46. Weiss W.F., Young T.M., Roberts C.J. Principles, approaches, and challenges for predicting protein aggregation rates and shelf life. J. Pharm. Sci. 2009, 98:1246-1277.
47. Roberts C.J., Das T.K., Sahin E. Predicting solution aggregation rates for therapeutic proteins: approaches and challenges. Int. J. Pharm. 2011, 418:318-333.
48. Li Y., Ogunnaike B.A., Roberts C.J. Multi-variate approach to global protein aggregation behavior and kinetics: effects of pH, NaCl, and temperature for chymotrypsinogen A. J. Pharm. Sci. 2010, 99:645-662.
49. Filipe W., Hawe A., Carpenter J.F., Jiskoot W. Analytical approaches to assess the degradation of therapeutic proteins. Trends Anal. Chem. 2013, 49:118-125.
50. Guidance for Industry Quality Considerations in Demonstrating Biosimilarity to a Reference Protein Product, U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER) Center for Biologics Evaluation and Research (CBER) February 2012, Biosimilarity.
51. Specifications: test procedures and acceptance criteria for biotechnological/biological products Q6b, International Conference on Harmonisation of technical requirements for registration of pharmaceuticals for human use, Current step 4 version, Dated 10 march 1999.
52. Dubin P.L., Edwards S.L., Mehta M.S., Tomalia D. Quantitation of non-ideal behavior in protein size-exclusion chromatography. J. Chromatogr. 1993, 635:51-60.
53. Mant C.T., Parker J.M.R., Hodges R.S. Size-exclusion high-performance liquid chromatography of peptides: requirement for peptide standards to monitor column performance and non-Ideal behaviour. J. Chromatogr. 1987, 397:99-112.
54. Ricker R.D., Sandoval L.A. Fast, reproducible size-exclusion chromatography of biological macromolecules. J. Chromatogr. A 1996, 743:43-50.
55. Arakawa T., Philo J.S., Ejima D., Tsumoto D.K., Arisaka F. Aggregation analysis of therapeutic proteins. Part 1. BioProcess Int. 2006, 4:32-42.
56. Kamberi M., Chung P., DeVas R., Li L., Li Z., Ma X., Fields S., Riley C.M. Analysis of non-covalent aggregation of synthetic hPTH (1-34) by size-exclusion chromatography and the importance of suppression of non-specific interactions for a precise quantitation. J. Chromatogr. B 2004, 810:151-155.
57. Stulk K., Pacakova V., Ticha M. Some potentialities and drawbacks of contemporary size exclusion chromatography. J. Biochem. Biophys. Methods 2003, 56:1-13.
58. Ejima D., Yumioka R., Arakawa T., Tsumoto K. Arginine as an effective additive in gel permeation chromatography. J. Chromatogr. A 2005, 1094:49-55.
59. Yumioka R., Sato H., Tomizawa H., Yamasaki Y., Ejima D. Mobile phase containing arginine provides more reliable SEC condition for aggregation analysis. J. Pharm. Sci. 2010, 99:618-620.
60. Striegel A.M., Yau W.W., Kirkland J.J., Bly D.D. Modern size exclusion liquid chromatography 2009, John Wiley and Sons Inc., Hoboken, New Jersey.
61. Wydham K., Walter T., Iraneta P., Alden B., Bouvier E., Hudallah C., Lawrence N., Walsh D. LCGC No. America, Recent Developments in LC Column Technology iQ(SA) 2012, 20.
62. Hagel L., Lundstrom H., Andersson T., Lindblom H. Properties, in theory and practice, of novel gel filtration media for standard liquid chromatography. J. Chromatogr. 1989, 476:329-344.
63. Kopaciewicz W., Regnier F.E. Non-ideal size-exclusion chromatography of proteins: effects of pH at low ionic strength. Anal. Biochem. 1982, 126:8-16.
64. Engelhardt H., Schon U. Optimal conditions for size exclusion chromatography of proteins. Chromatographia 1986, 22:388-390.
65. Hasegawa M., Kitano H. The effect of pore-size distribution on the binding of proteins to porous resin beads. Biotechnol. Bioeng. 1991, 37:608-613.
66. Ziegler A., Zaia J. Size-exclusion chromatography of heparin oligosaccharides at high and low pressure. J. Chromatogr. A 2006, 837:76-86.
67. Qian J., Tang Q., Cronin B., Markovich R., Rustum A. Development of a high performance size exclusion chromatography method to determine the stability of human serum albumin in a lyophilized formulation of interferon alfa-2b. J. Chromatogr. A 2008, 1194:48-56.
68. Aitken A., Learmonth M. Protein determination by UV absorption. In the Protein Protocols Handbook 1996, 3-6. Humana Press, Totowa, NJ, USA. J.M. Walker (Ed.).
69. Wolf P.A. Critical reappraisal of Waddell's technique for ultraviolet spectrophotometric protein estimation. Anal. Biochem. 1983, 129:145-155.
70. Fekete S., Dong M.W., Zang T., Guillarme D. High resolution reversed phase analysis of recombinant monoclonal antibodies by ultra-high pressure liquid chromatography column coupling. J. Pharm. Biomed. Anal. 2013, 83:273-278.
71. Fekete S., Rudaz S., Fekete J., Guillarme D. Analysis of recombinant monoclonal antibodies by RPLC: toward a generic method development approach. J. Pharm. Biomed. Anal. 2012, 70:158-168.
72. Diress A., Lorbetskie B., Larocque L., Li X., Alteen M., Isbrucker R., Girard M.M. Study of aggregation, denaturation and reduction of interferon alpha-2 products by size-exclusion high-performance liquid chromatography with fluorescence detection and biological assays. J. Chromatogr. A 2010, 1217:3297-3306.
73. Gunturi S.R., Ghobrial I., Sharma B. Development of a sensitive size exclusion HPLC method with fluorescence detection for the quantitation of recombinant human erythropoietin (r-HuEPO) aggregates. J. Pharm. Biomed. Anal. 2007, 43:213-221.
74. Principles of Fluorescence Spectroscopy 2006, 529-575. Springer Science+Business Media, LLC, New York, NY, USA. J.R. Lakowicz (Ed.).
75. Pothecary M., Ball S., Clarke P. Protein applications for advanced multi-detector size-exclusion chromatography. Chromatogr. Today 2012, 5:32-35.
76. Belauieu M., Corredig M., Turgeon S.L., Wicker L., Doublier J.L. The formation of heat-induced protein aggregates in whey protein/pectin mixtures studied by size exclusion chromatography coupled with multi-angle laser light scattering detection. Food Hydrocol. 2005, 19:803-812.
77. Garcia M.C. The effect of the mobile phase additives on sensitivity in the analysis of peptides and proteins by high-performance liquid chromatography-electrospray mass spectrometry. J. Chromatogr. B 2005, 825:111-123.
78. Gadgil H.S., Ren D., Rainville P., Mazzeo J.R., Russell R.J. A novel sec-ms method for the study of proteins and their interactions. Presented ASMS 2003.
79. Liu H., Bulseco G., Chumsae C. Analysis of reduced monoclonal antibodies using size exclusion chromatography coupled with mass spectrometry. J. Am. Soc. Mass Spectrom. 2009, 20:2258-2264.
80. Lazar A.C., Wang L., Blattler W.A., Amphlett G., Lambert J.M., Zhang W. Analysis of the composition of immunoconjugates using size-exclusion chromatography coupled to mass spectrometry. Rapid Commun. Mass Spectrom. 2005, 19:1806-1814.
81. Cavanagh J., Benson L.M., Thompson R., Naylor S. In-Line desalting mass spectrometry for the study of noncovalent biological complexes. Anal. Chem. 2003, 14:3281-3286.
82. Chakraborty A., Chen W., Mazzeo J. A Generic on-line UPLC-SEC-UV-MS method for the analysis of reduced monoclonal antibodies, Waters Corporation, Application Note 720004018EN 2011.
83. Pretorius N.O., Rode K., Simpson J.M., Pasch H. Analysis of complex phthalic acid based polyesters by the combination of size exclusion chromatography and matrix-assisted laser desorption/ionization mass spectrometry. Anal. Chim. Acta 2014, 808:94-103.
84. Hofe T., Reinbold G., McConville J. The challenge of using small particle packing materials in SEC/GPC, risks and possibilities. Chromatogr. Today 2011, 4:18-23.
85. Martin M., Guiochon G. Effects of high pressure in liquid chromatography. J. Chromatogr. A 2005, 1090:16-38.
86. Vajda J., Römling R. New approaches to HPLC analysis of antibody aggregates and fragments. Chromatogr. Today 2012, 5:44-47.
87. Liu Y., Radke W., Pasch H. Coil-stretch transition of high molar mass polymers in packed-column hydrodynamic chromatography. Macromolecules 2005, 38:7476-7484.
88. Fekete S., McCalley D.V., Veuthey J.L., Guillarme D. The effect of pressure, mobile phase velocity on the retention properties of small analytes large biomolecules in ultra-high pressure liquid chromatography. J. Chromatogr. A 2012, 1270:127-138.
89. Fekete S., Horváth K., Guillarme D. Influence of pressure and temperature on molar volume and retention properties of peptides in ultra-high pressure liquid chromatography. J. Chromatogr. 2013, 111:65-71.
90. Randolph T.W., Seefeldt M., Carpenter J.F. High hydrostatic pressure as a tool to study protein aggregation and amyloidosis. Biochim. Biophys. Acta 2002, 1595:224-234.
91. Rivalain N., Roquain J., Demazeau G. Development of high hydrostatic pressure in biosciences: pressure effect on biological structures and potential applications in biotechnologies. Biotechnol. Adv. 2010, 28:659-672.
92. Pellerin V.L., Balny C. High pressure as a tool to study some proteins properties: conformational modification, activity and oligomeric dissociation. Inn Food Sci. Emerg. Technol. 2002, 3:209-221.
93. Anón M.C., de Lamballerie M., Speroni F. Effect of high pressure on solubility and aggregability of calcium-added soybean proteins. Inn. Food Sci. Emerg. Technol. 2012, 16:155-162.
94. Torrent J., Martinez M.T.A., Harricane M.C., Heitz F., Liautard J.P., Balny C., Lange R. High pressure induces scrapie-like prion protein misfolding and amyloid fibril formation. Biochemistry 2004, 43:7162-7170.
95. Woodard J., Lau H., Latypov R.F. Nondenaturing size-exclusion chromatography-mass spectrometry to measure stress-induced aggregation in a complex mixture of monoclonal antibodies. Anal. Chem. 2013, 85:6429-6436.
96. Hawe A., Friess W., Sutter M., Jiskoot W. Online fluorescent dye detection method for the characterization of immunoglobulin G aggregation by size exclusion chromatography and asymmetrical flow field flow fractionation. Anal. Biochem. 2008, 378:115-122.
97. Grotefend S., Kaminski L., Wroblewitz S., Deeb S.E., Kühn N., Reichl S., Limberger M., Watt S., Wätzig H. Protein quantitation using various modes of high performance liquid chromatography. J. Pharm. Biomed. Anal. 2012, 71:127-138.
98. Rea J.C., Lou Y., Cuzzi J., Hu Y., Jong I., Wang Y.J., Farnan D. Development of capillary size exclusion chromatography for the analysis of monoclonal antibody fragments extracted from human vitreous humor. J. Chromatogr. A 2012, 1270:111-117.
99. Rea J.C., Moreno G.T., Vampola L., Lou Y., Haan B., Tremintin G., Simmons L., Nava A., Wang Y.J., Farnan D. Capillary size exclusion chromatography with picogram sensitivity for analysis of monoclonal antibodies purified from harvested cell culture fluid. J. Chromatogr. A 2012, 1219:140-146.
100. Wong C., Mills C.S., Burman S. Facile method of quantification for oxidized tryptophan degradants of monoclonal antibody by mixed mode ultra performance liquid chromatography. J. Chromatogr. A 2012, 1270:153-161.
101. King H.D., Dubowchik G.M., Mastalerz H., Willner D., Hofstead S.J., Firestone R.A., Lasch S.J., Trail P.A. Monoclonal antibody conjugates of doxorubicin prepared with branch peptide linkers: inhibition of aggregation by methoxytriethileneglicol chains. J. Med. Chem. 2002, 45:4336-4343.
102. Hollander I., Kunz A., Hamann P.R. Selection of reaction additives used in the preparation of monomeric antibody-calicheamicin conjugates. Bioconjug. Chem. 2008, 19:358-361.
103. Quiles S., Raisch K.P., Sanford L.L., Bonner J.A., Safavy A. Synthesis and preliminary biological evaluation of high-drug-load paclitaxel-antibody conjugates for tumor-targeted chemotherapy. J. Med. Chem. 2010, 53:586-594.
104. Sun M.M., Beam K.S., Cerveny C.G., Hamblett K.J., Blackmore R.S., Torgov M.Y. Reduction-alkylation strategies for the modification of specific monoclonal antibody disulfides. Bioconjugate Chem. 2005, 16:1282-1290.
105. Rousset E.W., Bussat M.C.J., Colas O., Excoffier M., Haeuw J.F., Rilatt I., Perez M., Corvaïa N., Beck A. Antibody drug conjugate model fast characterization by LC-MS following IdeS proteolytic digestion. mAbs 2013, 6:173-184.
106. Stephen K., Hong P., Fountain K.J. Size-exclusion ultra performance liquid chromatography analysis of insulin. Chromatography Online 2012.
107. Ye H. Simultaneous determination of protein aggregation, degradation, and absolute molecular weight by size exclusion chromatography-multiangle laser light scattering. Anal. Biochem. 2006, 356:76-85.
108. He Y., Friese O.V., Schlittler M.R., Wang Q., Yang X., Bass L.A., Jones M.T. On-line coupling of size exclusion chromatography with mixed-mode liquid chromatography for comprehensive profiling of biopharmaceutical drug product. J. Chromatogr. A 2012, 1262:122-129.
109. Farnan D., Moreno G., Stults J., Becker A., Tremintin G., van Gils M. J. Chromatogr. A 2009, 1216:8904-8909.
110. Gazal E. Can size exclusion chromatography (SEC) be done on sub-3 um particles?. Presented at the 17th annual meeting of the Israel Analytical Chemistry Society 2014, Tel Aviv, Israel.
111. Koza S.M., Hong P., Fountain K.J. Advantages of ultra performance liquid chromatography using 125 Å pore size, sub-2 μm particles for the analysis of peptides and small proteins. Poster Presented at Medimmune 2012.
112. Aggarwal S. What's fueling the biotech engine - 2012 to 2013. Nat. Biotechnol. 2014, 32:32-39.
113. Debaene F., Rousset E.W., Colas O., Ayoub D., Corvaïa N., Van Dorsselaer A., Beck A., Cianférani S. Time resolved native ion-mobility mass spectrometry to monitor dynamics of IgG4 Fab arm exchange and "bispecific" monoclonal antibody formation. Anal. Chem. 2013, 85:9785-9792.
114. Beck A., Reichert J. Therapeutic Fc-fusion proteins and peptides as successful alternatives to antibodies. mAbs 2011, 3:415-416.